FDA gives clearance and CLIA waiver to second generation sexual health test
Visby Medical has announced its second generation point of care test for detecting sexually transmitted diseases in women has received 510(k) clearance and a CLIA waiver from the FDA.
The FDA has given 510(k) clearance and a CLIA waiver to Visby Medical’s second generation point of care (POC) test for identifying sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis in women.
STIs reached an all-time high for 6 years in a row in 2022, but STI testing often has a 2 to 5 day or more time-to-diagnosis. Additionally, gonorrhea and chlamydia alone saw a 30% increase from 2015 to 2019.
The Visby Medical Sexual Health POC test is the first “instrument-free” platform offering true polymerase chain reaction technology and is small enough to fit in the palm of one’s hand. It allows accurate test results to be determined in under 30 minutes, giving clinicians the opportunity to accurately test, talk, and treat patients in a single visit.
Significant improvements in workflow can be granted from the device, which turns 4 actions into 1 with 97% accuracy. Manufacturability and reliability are also improved from the previous model.
According to Gary Schoolnik, MD, chief medical officer at Visby Medicaland professor of medicine at stanforduniversity, the Visby platform will allow clinicians to make informed decisions on treatment in 1 visit. It will also reduce the risk of pelvic inflammatory disease in an infected patient, expedite the treatment of patients’ sexual partners, and lessen the spread of STIs.
"Fast and accurate results mean we can usually keep our 'door to discharge time' under 1 hour—patients have a convenient, complete engagement, and we can provide appropriate care without the risk of unnecessary antibiotics that can happen when a definitive diagnosis is delayed,” said Lamont Tyler, MD, market medical director of CareNow Urgent Care Henderson, Nevada.
Reference
Visby Medical receives FDA clearance and CLIA waiver for second generation sexual health test for women. Visby Medical. March 14, 2023. Accessed March 21, 2023. https://www.prnewswire.com/news-releases/visby-medical-receives-fda-clearance-and-clia-waiver-for-second-generation-sexual-health-test-for-women-301771495.html
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
